BLOOD PRESSURE REDUCTION WITH THE NOVEL DUAL-ACTING ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR LCZ696: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR STUDY

Michael Bö;hm; Luis M. Ruilope; Yves Lacourciere; Andrej Dukat; Jim Gong; Martin Lefkowitz

doi:10.1016/s0735-1097(10)60585-2

BLOOD PRESSURE REDUCTION WITH THE NOVEL DUAL-ACTING ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR LCZ696: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE-COMPARATOR STUDY

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(10)60585-2 ◽

2010 ◽

Vol 55 (10) ◽

pp. A61.E584

Author(s):

Michael Bö;hm ◽

Luis M. Ruilope ◽

Yves Lacourciere ◽

Andrej Dukat ◽

Jim Gong ◽

...

Keyword(s):

Blood Pressure ◽

Blood Pressure Reduction ◽

The Novel ◽

Pressure Reduction ◽

Angiotensin Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Active Comparator ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

The Lancet ◽

10.1016/s0140-6736(09)61966-8 ◽

2010 ◽

Vol 375 (9722) ◽

pp. 1255-1266 ◽

Cited By ~ 324

Author(s):

Luis Miguel Ruilope ◽

Andrej Dukat ◽

Michael Böhm ◽

Yves Lacourcière ◽

Jianjian Gong ◽

...

Keyword(s):

Blood Pressure ◽

Angiotensin Ii ◽

Blood Pressure Reduction ◽

Pressure Reduction ◽

Angiotensin Ii Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Active Comparator

Download Full-text

A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

Expert Opinion on Investigational Drugs ◽

10.1080/13543784.2021.1985464 ◽

2021 ◽

Author(s):

Yue Hu ◽

Hong Zhang ◽

Xiaojiao Li ◽

Jiajia Mai ◽

Lizhi Yang ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Dose Escalation ◽

Multiple Dose ◽

Phase I Clinical Trial ◽

Angiotensin Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text

A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a β-blocker on blood pressure reduction

Clinical Therapeutics ◽

10.1016/j.clinthera.2008.11.003 ◽

2008 ◽

Vol 30 (11) ◽

pp. 2030-2039 ◽

Cited By ~ 4

Author(s):

David S. Wald ◽

Malcolm Law ◽

Sarah Mills ◽

Jonathan P. Bestwick ◽

Joan K. Morris ◽

...

Keyword(s):

Blood Pressure ◽

Angiotensin Converting Enzyme ◽

Crossover Trial ◽

Enzyme Inhibitor ◽

Blood Pressure Reduction ◽

Pressure Reduction ◽

Converting Enzyme ◽

Double Blind ◽

Double Blind Placebo ◽

Β Blocker

Download Full-text

Faculty Opinions recommendation of The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955094.793462652 ◽

2012 ◽

Author(s):

Chim Lang

Keyword(s):

Heart Failure ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Randomised Controlled

Download Full-text

The natriuretic effect of angiotensin receptor blockers is not attributable to blood pressure reduction during the previous night, but to inhibition of tubular sodium reabsorption

Journal of the Renin-Angiotensin-Aldosterone System ◽

10.1177/1470320313518253 ◽

2014 ◽

Vol 15 (3) ◽

pp. 316-318 ◽

Cited By ~ 3

Author(s):

Toshiyuki Miura ◽

Shuichi Watanabe ◽

Maki Urushihara ◽

Hiroyuki Kobori ◽

Michio Fukuda

Keyword(s):

Blood Pressure ◽

Angiotensin Receptor Blockers ◽

Blood Pressure Reduction ◽

Sodium Reabsorption ◽

Pressure Reduction ◽

Angiotensin Receptor ◽

Previous Night ◽

Tubular Sodium Reabsorption ◽

Receptor Blockers ◽

Natriuretic Effect

Download Full-text

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(12)61227-6 ◽

2012 ◽

Vol 380 (9851) ◽

pp. 1387-1395 ◽

Cited By ~ 637

Author(s):

Scott D Solomon ◽

Michael Zile ◽

Burkert Pieske ◽

Adriaan Voors ◽

Amil Shah ◽

...

Keyword(s):

Heart Failure ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Randomised Controlled

Download Full-text

Combination Angiotensin Receptor Blocker-Neutral Endopeptidase Inhibitor Provides Additive Blood Pressure Reduction Over Angiotensin Receptor Blocker Alone

Journal of Clinical Hypertension ◽

10.1111/j.1751-7176.2010.00358.x ◽

2010 ◽

Vol 12 (10) ◽

pp. 809-812 ◽

Cited By ~ 11

Author(s):

Michael J. Bloch ◽

Jan N. Basile

Keyword(s):

Blood Pressure ◽

Angiotensin Receptor Blocker ◽

Blood Pressure Reduction ◽

Neutral Endopeptidase ◽

Receptor Blocker ◽

Pressure Reduction ◽

Angiotensin Receptor

Download Full-text

Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension

Advances in Therapy ◽

10.1007/s12325-014-0097-9 ◽

2014 ◽

Vol 31 (2) ◽

pp. 243-243

Author(s):

Luis Ruilope ◽

Angie Schaefer

Keyword(s):

Blood Pressure ◽

Blood Pressure Reduction ◽

Fixed Dose ◽

Pressure Reduction ◽

Double Blind Trial ◽

Double Blind ◽

Aortic Blood ◽

Dose Combination ◽

Aortic Blood Pressure ◽

Central Aortic Blood Pressure

Download Full-text

BLOOD PRESSURE REDUCTION WITH ANGIOTENSIN RECEPTOR BLOCKER THERAPY IN REN C-5312T GENETIC VARIANT

Journal of Hypertension ◽

10.1097/01.hjh.0000469859.54435.60 ◽

2015 ◽

Vol 33 ◽

pp. e37

Author(s):

Mifetika Lukitasari ◽

Mohammad Saifur Rohman ◽

Arina Madjidi ◽

ValerinnaYogibuana Swastika Putri ◽

Supono ◽

...

Keyword(s):

Blood Pressure ◽

Angiotensin Receptor Blocker ◽

Genetic Variant ◽

Blood Pressure Reduction ◽

Receptor Blocker ◽

Pressure Reduction ◽

Angiotensin Receptor ◽

Blocker Therapy

Download Full-text

Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension

Advances in Therapy ◽

10.1007/s12325-014-0113-0 ◽

2014 ◽

Vol 31 (4) ◽

pp. 472-472

Author(s):

Luis Ruilope ◽

Angie Schaefer

Keyword(s):

Blood Pressure ◽

Blood Pressure Reduction ◽

Fixed Dose ◽

Pressure Reduction ◽

Double Blind Trial ◽

Double Blind ◽

Aortic Blood ◽

Dose Combination ◽

Aortic Blood Pressure ◽

Central Aortic Blood Pressure

Download Full-text